scholarly journals Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features

2016 ◽  
Vol 124 (12) ◽  
pp. 893-900 ◽  
Author(s):  
Xiaoyin “Sara” Jiang ◽  
Grant P. Harrison ◽  
Michael B. Datto
Keyword(s):  
Thyroid Neoplasm ◽  
Molecular Testing ◽  
Young Investigator ◽  
Nuclear Features

Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP)

2018 ◽  
Vol 29 (1) ◽  
pp. 68-74 ◽  
Author(s):  
Kyle C. Strickland ◽  
Markus Eszlinger ◽  
Ralf Paschke ◽  
Trevor E. Angell ◽  
Erik K. Alexander ◽  
...  
Keyword(s):  
Thyroid Neoplasm ◽  
Molecular Testing ◽  
Cytologic Diagnosis ◽  
Non Invasive ◽  
Nuclear Features

scholarly journals Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: Some insights into their identification

2016 ◽  
Vol 124 (10) ◽  
pp. 699-710 ◽  
Author(s):  
Tommaso Bizzarro ◽  
Maurizio Martini ◽  
Sara Capodimonti ◽  
Patrizia Straccia ◽  
Celestino Pio Lombardi ◽  
...  
Keyword(s):  
Thyroid Neoplasm ◽  
Young Investigator ◽  
Liquid Based Cytology ◽  
Morphologic Analysis ◽  
Nuclear Features

scholarly journals Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity

2020 ◽  
Vol 9 (3) ◽  
pp. R47-R58 ◽  
Author(s):  
Klaudia Zajkowska ◽  
Janusz Kopczyński ◽  
Stanisław Góźdź ◽  
Aldona Kowalska
Keyword(s):  
Western Europe ◽  
Benign Lesion ◽  
Distant Metastases ◽  
Thyroid Stimulating Hormone ◽  
Adverse Outcomes ◽  
High Rate ◽  
Thyroid Neoplasm ◽  
Molecular Testing ◽  
Papillary Thyroid ◽  
Nuclear Features

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a borderline thyroid tumour formerly known as noninvasive encapsulated follicular variant of papillary thyroid carcinoma. The prevalence of NIFTP is estimated at 4.4–9.1% of all papillary thyroid carcinomas worldwide; however, the rate of occurrence of NIFTP is eight times lower in Asian countries than in Western Europe and America. At the molecular level, NIFTP is characterised by the lack of BRAF V600E and BRAF V600E-like mutations or other high-risk mutations (TERT, TP53) and a high rate of RAS mutations, which is similar to other follicular-pattern thyroid tumours. The diagnosis of NIFTP can only be made after histological examination of the entire tumour removed during surgery and is based on strictly defined inclusion and exclusion criteria. Although the diagnosis is postoperative, the combination of certain findings of preoperative tests including ultrasonography, cytology, and molecular testing may raise suspicion of NIFTP. These tumours can be effectively treated by lobectomy, although total thyroidectomy remains an option for some patients. Radioactive iodine and thyroid stimulating hormone suppression therapy are not required. NIFTP has an extremely good prognosis, even when treated conservatively with lobectomy alone. Nevertheless, it cannot be considered as a benign lesion. The risk of adverse outcomes, including lymph node and distant metastases, is low but not negligible.

Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact on the reclassification of thyroid nodules

2018 ◽  
Vol 25 (4) ◽  
pp. R247-R258 ◽  
Author(s):  
Isabel Amendoeira ◽  
Tiago Maia ◽  
Manuel Sobrinho-Simões
Keyword(s):  
Thyroid Neoplasm ◽  
Molecular Testing ◽  
Predictive Values ◽  
Non Invasive ◽  
Molecular Tests ◽  
Endocrine Organs ◽  
The Impact ◽  
Nuclear Features

The 2017 edition of the WHO book on Classification of Tumours of Endocrine Organs includes a new section entitled ‘Other encapsulated follicular-patterned thyroid tumours’, in which the newly created NIFTP (non-invasive follicular thyroid neoplasm with papillary-like nuclear features) is identified and described in detail. Despite deleting the word ‘carcinoma’ from its name, NIFTP is not a benign tumor either and is best regarded as a neoplasm with ‘very low malignant potential’. The main goal of the introduction of NIFTP category is to prevent overdiagnosis and overtreatment. Sampling constraints, especially when dealing with heterogeneous and/or large nodules, and difficulties in the invasiveness evaluation, are the major weaknesses of the histological characterization of NIFTP. At the cytological level, NIFTP can be separated from classic papillary carcinoma (cPTC) but not from encapsulated, invasive follicular variant PTC. The impact of NIFTP individualization for cytopathology is the drop of rates of malignancy for each Bethesda category in general and for indeterminate categories in particular. The biggest impact will be seen in institutions with a high frequency of FVPTC. The introduction of NIFTP has changed the utility of predictive values of molecular tests because RAS mutations and PAX8-PPARg rearrangements are frequently detected in NIFTP. This turns less promising the application of mutation detection panels as indicators of malignancy and will probably contribute to switch to a rule-out approach of molecular testing. Selection for surgery will go on being determined by a combined detection of clinical, cytological and ultrasound suspicious features.

scholarly journals Cytomorphology of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and the Impact of New Nomenclature on Molecular Testing

2019 ◽  
Vol 7 (2) ◽  
pp. 15 ◽  
Author(s):  
Rupendra T. Shrestha ◽  
Darin Ruanpeng ◽  
James V. Hennessey
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Preoperative Assessment ◽  
Braf V600e ◽  
Thyroid Neoplasm ◽  
Molecular Testing ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
The Impact ◽  
Nuclear Features

The re-naming of noninvasive follicular variant papillary thyroid cancer to the apparently non-malignant, noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) impacts the prevalence of malignancy rates, thereby affecting mutation frequency in papillary thyroid cancer. Preoperative assessment of such nodules could affect management in the future. The original publications following the designation of the new nomenclature have been extensively reviewed. With the adoption of NIFTP terminology, a reduction in the follicular variant of papillary thyroid cancer (FVPTC) prevalence is anticipated, as is a modest reduction of papillary thyroid cancer (PTC) prevalence that would be distributed mainly across indeterminate thyroid nodules. Identifying NIFTP preoperatively remains challenging. RAS mutations are predominant but the presence of BRAF V600E mutation has been observed and could indicate inclusion of the classical PTC. The histological diagnosis of NIFTP to designate low-risk encapsulated follicular variant papillary thyroid cancers (EFVPTCs) would impact malignancy rates, thereby altering the mutation prevalence. The histopathologic criteria have recently been refined with an exclusion of well-formed papillae. The preoperative identification of NIFTP using cytomorphology and gene testing remains challenging.

scholarly journals Risk of Malignancy in Thyroid Nodules Using the American College of Radiology Thyroid Imaging Reporting and Data System in the NIFTP Era

2018 ◽  
Vol 50 (10) ◽  
pp. 735-737 ◽  
Author(s):  
Pedro Rosario ◽  
Alexandre da Silva ◽  
Maurício Nunes ◽  
Michelle Borges
Keyword(s):  
Thyroid Nodules ◽  
Data System ◽  
Thyroid Neoplasm ◽  
Malignant Tumours ◽  
Thyroid Imaging ◽  
Risk Of Malignancy ◽  
Nuclear Features

AbstractRecently, the American College of Radiology (ACR) proposed a Thyroid Imaging Reporting and Data System (TI-RADS) for thyroid nodules based on ultrasonographic features. It is important to validate this classification in different centres. The present study evaluated the risk of malignancy in solid nodules>1 cm using ACR TI-RADS. The risk of malignancy was defined including noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and after its exclusion from malignant tumours. For the present study, the original images were revised, and each nodule was assigned to one of the TI-RADS levels proposed for solid nodules: TR3, TR4, or TR5. This risk of malignancy was significantly different for the three levels: 1.7%, 11.2%, and 60.6% for TR3, TR4, and TR5, respectively, when NIFTP was included, and 0.6%, 7.9%, and 60.2% for TR3, TR4, and TR5, respectively, when NIFTP was excluded from malignant tumours. The nodules corresponding to NIFTP were classified according to ACR as TR3 in 28.5% of cases, TR4 in 67.8%, and TR5 in only 3.5%. The nodules corresponding to cancer were classified according to ACR as TR3 in only 2.3% of cases, TR4 in 27%, and TR5 in 70.5%. In conclusion, this study shows the validity of the ACR TI-RADS for solid thyroid nodules, even after the exclusion of NIFTP from malignant tumours.

Does noninvasive follicular thyroid neoplasm with papillary-like nuclear features have distinctive features on sonography?

2017 ◽  
Vol 46 (2) ◽  
pp. 139-147 ◽  
Author(s):  
Tamar C. Brandler ◽  
Joseph Yee ◽  
Fang Zhou ◽  
Margaret Cho ◽  
Joan Cangiarella ◽  
...  
Keyword(s):  
Thyroid Neoplasm ◽  
Distinctive Features ◽  
Nuclear Features
Sign in / Sign up

Export Citation Format

Share Document